Skip to main content
Clinical Trials/NCT00769275
NCT00769275
Completed
Not Applicable

Detection of Ischemia in Asymptomatic Diabetics

Yale University1 site in 1 country1,123 target enrollmentAugust 2000

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Type 2 Diabetes Mellitus
Sponsor
Yale University
Enrollment
1123
Locations
1
Primary Endpoint
Prevalence of silent myocardial ischemia in subjects randomized to screening was 22%.
Status
Completed
Last Updated
17 years ago

Overview

Brief Summary

Asymptomatic subjects with Type 2 Diabetes Mellitus were randomized to either screening with Tc-99m sestamibi adenosine SPECT imaging or no screening. All patients will be followed for 5 years for the occurrence of cardiac death or non-fatal myocardial infarction.

The aims are:

  1. To prospectively assess the prevalence of silent myocardial ischemia in asymptomatic subjects with Type 2 Diabetes Mellitus.
  2. To identify on the basis of clinical and/or biochemical variables in a high-risk cohort in which screening for coronary artery disease is appropriate.
  3. To assess progression of (silent) myocardial ischemia after 3 years.
  4. To assess the occurence of cardiac death or nonfatal myocardial infarction during 5 years follow-up in screened and not screened subjects.
Registry
clinicaltrials.gov
Start Date
August 2000
End Date
January 2008
Last Updated
17 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age 50-75 years
  • Type 2 diabetes mellitus

Exclusion Criteria

  • Angina or anginal equivalent
  • Abnormal rest ECG (Q or ST depression)
  • Known CAD
  • Stress testing within the last 3 years

Outcomes

Primary Outcomes

Prevalence of silent myocardial ischemia in subjects randomized to screening was 22%.

Time Frame: At study entry

Overall cardiac event rate (cardiac death, myocardial infarction) was 3.0%, not different in screened and not screened cohort

Time Frame: 5 years

At repeat stress imaging three years after recruitment 79% of subjects showed resolution of ischemia, whereas only 10% developed new ischemia.

Time Frame: 3 years after start

Study Sites (1)

Loading locations...

Similar Trials